title: Combined treatment for Coats' disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases.
abstract: BACKGROUND
  The exact pathogenetic mechanisms of Coats' disease remain unknown. In this report, we show two cases of Coats' disease that achieved a favorable prognosis with the combined treatment of intravitreal bevacizumab (IVB) injection prior to photocoagulation, although both initially resisted photocoagulation therapy.
  
  
  METHODS
  Case 1 was a 15-year-old boy with initial visual acuity of 0.4 OD. At the temporal retina, aneurysms and abnormal telangiectatic vessels were observed. Hard exudates and an exudative retinal detachment extended to the fovea. He was diagnosed as having Coats' disease at stage 3A and we performed laser photocoagulation as an initial approach to treat peripheral aneurysms and telangiectatic vessels. After the treatment, the exudative retinal detachment was eased and visual acuity improved to 1.0; however, recurrence occurred after 5 months. The exudative change was resistant against laser photocoagulation therapy and we therefore added IVB as an adjuvant before photocoagulation. Fourteen days after IVB injection phased laser photocoagulation was given to cover the abnormal capillaries, aneurysms and the leakage area spotted in FA. A good prognosis was obtained with decreased exudation and improved visual acuity.Case 2 was an 11-year-old boy with decreased visual acuity of 0.15 OS at the initial visit. Hard exudates, retinal edema and serous retinal detachment were seen at the macula and peripheral retina. Fluorescein angiography revealed telangiectatic capillaries at the temporal retina. Our diagnosis was Coats' disease at stage 3A. Extensive photocoagulation was performed as an initial treatment to the lesion. However, the exudative change was severe and resistant against the photocoagulation treatment. Therefore, we added IVB as an adjuvant before photocoagulation. Exudative change in the retina seemed to be eased 7 days after IVB injection, therefore, phased laser phototherapy was added to cover the abnormal capillaries. After the combination therapy, exudative change was remarkably ameliorated and better visual acuity was achieved.
  
  
  CONCLUSIONS
  Bevacizumab is considered an effective adjuvant for Coats' disease with exudative change resistant to retinal photocoagulation therapy.
authors.forename: Aya
authors.initials: A
authors.lastname: Kodama
authors.affiliation: Department of Ophthalmology, Kinki University Faculty of Medicine, 377-2, Ohnohigashi, Osaka-Sayama City, Osaka 589-8511, Japan. sugioka@med.kindai.ac.jp.
authors.forename: Koji
authors.initials: K
authors.lastname: Sugioka
authors.forename: Shunji
authors.initials: S
authors.lastname: Kusaka
authors.forename: Chota
authors.initials: C
authors.lastname: Matsumoto
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Shimomura
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D002648:Child; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000379:methods; D008297:Male; D058456:Retinal Telangiectasis / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab